U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Daratumumab

Last Revision: November 15, 2023.

Estimated reading time: 1 minute

CASRN: 945721-28-8

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of daratumumab during breastfeeding. Because daratumumab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3] However, daratumumab is administered with lenalidomide, pomalidomide, or thalidomide, three drugs that have no information on use in nursing mothers. For this reason, the manufacturer recommends that women receiving daratumumab should not breastfeed.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
2.
Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
3.
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]

Substance Identification

Substance Name

Daratumumab

CAS Registry Number

945721-28-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal, Humanized

Antineoplastic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500781PMID: 29999840

Views

Related information

Similar articles in PubMed

  • Review Tremelimumab.[Drugs and Lactation Database (...]
    Review Tremelimumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Alemtuzumab.[Drugs and Lactation Database (...]
    Review Alemtuzumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Bezlotoxumab.[Drugs and Lactation Database (...]
    Review Bezlotoxumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Atezolizumab.[Drugs and Lactation Database (...]
    Review Atezolizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Evolocumab.[Drugs and Lactation Database (...]
    Review Evolocumab.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...